ArticleHeliyon2025
Hyperbaric oxygen therapy improves the effects of systemic steroid therapy for sudden sensorineural hearing loss.
Article in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Stellate Ganglion Block Combined with Hyperbaric Oxygen Therapy for Sudden Sensorineural Hearing Loss: A Retrospective Three-Arm Study.Life (Basel, Switzerland) · 2026Article
- Pathophysiologic phenotyping of idiopathic sudden sensorineural hearing loss: toward precision management.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Review
- Interaction-aware dexterous robot for minimally invasive transcanal inner ear interventions.Nature communications · 2026Article
- Hyperbaric Oxygen Therapy for Idiopathic Sudden Sensorineural Hearing Loss: Factors Affecting Benefits of Earlier Start and Longer Treatment Duration.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to investigate the therapeutic efficacy of combined hyperbaric oxygen therapy (HBOT) and steroid therapy in treating sudden sensorineural hearing loss (SSNHL). Design: This retrospective analysis included 505 patients diagnosed with SSNHL from August 2017 to July 2022. The patients received either a systemic steroid (SS) alone or SS with HBOT. Hearing improvement was evaluated with pure-tone audiometry (PTA). Among the participants, 102 received SS + HBOT, whereas 403 were treated with SS alone. Results: The SS + HBOT group demonstrated significantly better improvement in the PTA threshold averaged across four low frequencies (PTA Conclusions: HBOT improves the effectiveness of SS treatment in SSNHL, with notable benefits for younger patients and those with an initial hearing loss of >50 dB. HBOT exhibited more pronounced effects at lower frequencies. Initiating HBOT within 11 days of the SSNHL diagnosis is recommended, and a regimen of five sessions is indicated for optimal results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.